HBIO · Harvard Bioscience Inc
Market Cap
$36.24M
Shares
4.55M
Volume · Oct 2
15.47K
Avg daily vol (3M)
17.96K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.34
Open$8.08
Day$8.03–8.42
52W close$3.80–8.34
Avg vol 30d19K
Short int48K · 1.1% float · 2.6d
Short vol28%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
call held May 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$87.81M
Trailing 12 months
Net income (TTM)
−$10.41M
Trailing 12 months
Revenue growth YoY
+11.1%
Year over year
Operating margin
-0.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$30.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.1%
Latest settlement · 2.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+14%
above
RSI (14)
69
neutral
MACD trend
Negative
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+79%
trailing
YTD return
+24%
this year
Relative strength
+67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -0.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
37 holders — near 3-yr low, contrarian setup
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
43%
contracting
EPS growth
−357%
Y/Y
Free cash flow
$5.5M
Balance sheet
$27.3M
net debt
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
third quarter of 2026
Revenue
Initiated
$21M – $22.6M
prior qtr $22.73M
midpoint −4.1% QoQ
Adjusted gross margin
Non-GAAP
Initiated
56% – 58%
Adjusted EBITDA
Non-GAAP
Initiated
$1.5M – $2.5M
full-year 2026
Revenue growth
Initiated
3% – 5%
Adjusted gross margin
Non-GAAP
Initiated
57% – 59%
Adjusted EBITDA growth
Non-GAAP
Initiated
6% – 10%
Guided vs delivered
· last 2 settled
Revenues
full year 2024
guided $97M – $102M
$94.14M
Miss −5.4%
Revenues
full year 2023
guided $116M – $120M
$112.25M
Miss −4.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
69
Neutral
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.06% of float · ▼ -0.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
37 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $4
Now $8 · 100%
Range high $8
vs 200-day avg +33%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.4M | Six months ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 5.6% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margin non-GAAP | 58.3% | Six months ended June 30, 2026 | — |
| Adjusted operating margin non-GAAP | 3.1% | Six months ended June 30, 2026 | — |
| Gross margin | 55.6% | three months ended June 30, 2026 filing | — |
| Net debt | $33.5M | June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | $25.34M | Six Months Ended June 30, 2026 | — |
| Revenue on a constant currency basis non-GAAP | $42.69M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HBIO
this stock
Harvard Bioscience Inc
|
$36.24M | — | -3.8% | — | 1.1% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HBIO | +4.8% | +4.3% | +79.0% | +5.3% | +24.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +5.0% | +4.7% | +66.8% | +4.4% | +11.6% |